TearSolutions, Inc., a Charlotesville, VA-based biotech company developing therapies for the treatment of ocular surface related diseases, closed a $3M Series B funding round.
The company intends to use the funds to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages.
Led by Anil Asrani, President and CEO, TearSolutions is a biotechnology company focused on the discovery, development and commercialization of novel therapies for the treatment of patients with Ocular Surface Disease (OSD). The company is currently developing bioactive proprietary peptide proteoforms of lacritin.
Lacripep was patented by Dr. Gordon Laurie, a professor of Ophthalmology and Cell Biology at the University of Virginia, based on his NIH funded research into the composition of human tears, which led to the discovery of lacritin. Lacritin and Lacripep represent a unique treatment modality that optimizes all three layers of the tear film while restoring corneal health and homeostasis. The intellectual property is exclusively licensed to TearSolutions, Inc. from the University of Virginia Licensing and Ventures Group.
FinSMEs
21/11/2024